Oxurion reports positive topline Phase 1 results with THR-687
THR-687 (Pan RGD integrin antagonist)
THR-687, a pan RGD integrin antagonist, targets a broader spectrum of DR hallmarks. Preclinical models show that it is a potent inhibitor of angiogenesis-induced vascular leakage. The inhibition of integrins targets multiple processes involved in pathological angiogenesis and vascular leakage, unlike anti-VEGF treatment.
Oxurion has reported positive topline data from a Phase I clinical trial evaluating THR-687 for treatment of DME. A Phase II study is planned for mid 2021, evaluating THR-687 as a VEGF-independent treatment option in the treatment of naïve DME patients.
Phase I open-label, multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with DME
Completed - topline data reported
This Phase I study (THR-687-001 - NCT03666923) will primarily assess the safety of a single intravitreal injection of escalating dose levels of THR-687 in patients with DME. A total of 12 patients with DME have been enrolled into the US-based study (Clinicaltrials.gov: NCT03666923). Oxurion reported positive topline data and is currently preparing to initiate a Phase II study.
Topline data show that THR-687 is well-tolerated and safe. No dose-limiting toxicities or serious adverse events reported.
Rapid onset of action and prolonged effect on Best Corrected Visual Acuity (BCVA) seen across all doses of THR-687 following a single injection.
Preparing start of Phase 2 study evaluating THR-687 with treatment naïve DME patients.
Preparing to initiate a Phase 2 clinical trial
Preclinical studies have provided evidence that THR-687 is a potent and safe treatment, highlighting its ability to inhibit various significant stages in pathologic angiogenesis, a key factor leading to vision loss in diabetic eye disease. These preclinical data provide support for the clinical development of THR-687.